Nkarta, Inc.

NKTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2019
Revenue $0 $0 $115.0K
Cost of Revenue — — —
Gross Profit — — —
Gross Margin — — —
Operating Expenses
Research & Development $90.4M $96.7M $17.2M
SG&A Expense $31.6M $31.5M $5.2M
Operating Income $-122.0M $-128.2M $-22.3M
Operating Margin — — -19,433.9%
Interest Expense — — —
Pretax Income — — —
Income Tax Expense $0 $0 $0
Net Income $-104.1M $-108.8M $-21.1M
Net Margin — — -18,327.0%
EPS (Basic) $-1.41 $-1.60 $-14.41
EPS (Diluted) $-1.41 $-1.60 $-14.41
Shares Outstanding (Basic) 74.0M 67.9M 1.6M
Shares Outstanding (Diluted) 74.0M 67.9M 1.6M
Dividends Per Share $0.00 $0.00 —